Cargando…
RAS pathway regulation in melanoma
Activating mutations in RAS genes are the most common genetic driver of human cancers. Yet, drugging this small GTPase has proven extremely challenging and therapeutic strategies targeting these recurrent alterations have long had limited success. To circumvent this difficulty, research has focused...
Autores principales: | Al Mahi, Amira, Ablain, Julien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905719/ https://www.ncbi.nlm.nih.gov/pubmed/35234863 http://dx.doi.org/10.1242/dmm.049229 |
Ejemplares similares
-
Loss of NECTIN1 triggers melanoma dissemination upon local IGF1 depletion
por: Ablain, Julien, et al.
Publicado: (2022) -
SPRED1 deletion confers resistance to MAPK inhibition in melanoma
por: Ablain, Julien, et al.
Publicado: (2020) -
The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics
por: Jarell, Abel D, et al.
Publicado: (2007) -
Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
por: Morante, Marta, et al.
Publicado: (2022) -
RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
por: Herrero, Ana, et al.
Publicado: (2021)